Why PPPs might be the secret ingredient in India’s diagnostics growth story

India’s diagnostics industry is undergoing a major shift as public-private partnerships (PPPs) begin to emerge as a foundational growth lever for private service providers and public health systems alike. At the intersection of rising demand, underserved rural regions, and under-capacitated public health infrastructure, the PPP model offers a viable framework to bridge the gap. While traditional diagnostics chains have largely focused on metro and urban cash-pay markets, companies like Krsnaa Diagnostics Limited are pioneering an alternative strategy: high-volume, contract-driven diagnostics delivery via long-term government partnerships.

The PPP approach is now being looked at not only as a means to scale access but as a core business model that could potentially redefine the economics, trust, and sustainability of diagnostic services across India.

What makes the PPP model attractive for diagnostics service delivery in India?

The public-private partnership model allows diagnostic service providers to collaborate with government-run hospitals, community health centers, and state health missions to deliver radiology and pathology services at scale. Under this structure, the private player brings diagnostic equipment, trained personnel, digital platforms, and operational know-how, while the government provides infrastructure, patient volumes, and regulatory facilitation. In return, the diagnostics company typically operates under a fixed-fee contract, price schedule, or a per-test reimbursement model depending on the agreement.

This collaborative approach provides mutual benefits. For private players, the model offers access to assured volumes in exchange for lower prices, reduced customer acquisition costs, and infrastructure support. For the public health system, PPPs provide a path to modernize diagnostic infrastructure, increase service availability, and offer quality testing without large upfront capital expenditure. The National Health Systems Resource Centre and state health departments have issued several guides encouraging states to adopt this framework for secondary and tertiary care diagnostics.

Companies like Krsnaa Diagnostics Limited have leveraged this model to build scale in Tier-II and Tier-III regions where other diagnostic providers often hesitate to invest due to high capex or limited near-term monetization. The company’s strategy of targeting government tenders and embedding its services within state-run institutions has resulted in a strong revenue foundation supported by recurring test volumes. This has also enabled the company to develop deep regional networks across underserved geographies.

How have companies like Krsnaa Diagnostics leveraged PPPs to scale their operations?

Krsnaa Diagnostics Limited stands out as one of the few diagnostics companies in India to build its business model predominantly on the PPP framework. From its inception, the company pursued state-issued diagnostic contracts, winning tenders to set up pathology labs, MRI centers, and CT scan facilities inside public hospitals across multiple states. Today, the company operates over 4,000 centers across India, with its presence extending to 15 states and three Union Territories.

A major part of Krsnaa Diagnostics Limited’s success in the PPP domain comes from its ability to deliver cost-effective services while maintaining high quality through accreditations like CAP (College of American Pathologists) and ACR (American College of Radiology). These global recognitions strengthen institutional trust and enhance the credibility of the company among both state governments and patients.

The Rajasthan diagnostics PPP is a landmark example of this model in motion. As part of the state-wide initiative to upgrade diagnostic access, Krsnaa Diagnostics Limited was awarded a significant multi-year contract to deploy labs and imaging services across government hospitals. The company expects the rollout to contribute meaningfully to revenue beginning Q4 FY26, with a full-year impact anticipated in FY27. Its approach to execution includes cloud-based diagnostic workflows, teleradiology platforms, and a centralized lab network that allows real-time reporting from remote specialists.

What structural and operational advantages does the PPP route offer for diagnostics in India?

Public-private partnerships in diagnostics offer several structural advantages that are hard to replicate through conventional retail models. First, they ensure high-volume patient throughput, as public hospitals and community health centers typically have a consistent flow of patients, especially in rural and semi-urban areas. Second, infrastructure costs are lower because the private player often shares or leases existing government space, reducing capex burdens.

Another advantage lies in regulatory alignment. By working directly with state health departments, diagnostics companies can avoid redundant licensing, reduce operational roadblocks, and streamline integration with public health records. Moreover, PPPs often benefit from economies of scale since centralized procurement, bulk testing, and consolidated logistics allow companies to bring down per-test costs significantly.

The model also aligns well with India’s broader healthcare policy goals. National initiatives like the Ayushman Bharat Digital Mission, state-level insurance schemes, and the government’s push to digitize healthcare services all require a reliable diagnostics backbone. Public-private collaborations allow for faster rollouts of such services without placing the entire burden on government budgets.

Lastly, the PPP model enables diagnostics providers to build long-term visibility into their revenue pipeline. While pricing under PPPs is usually lower than retail market rates, the multi-year nature of contracts, volume predictability, and operational efficiencies create a stable cash-flow profile that is increasingly attractive to investors and lenders.

What challenges and risks remain for diagnostics PPPs in India?

Despite the upside, diagnostics PPPs are not without challenges. The most pressing concern for private players is delayed payments. Since state reimbursements often depend on budgetary releases or bureaucratic approvals, the receivables cycle can extend beyond 150 days, as acknowledged by Krsnaa Diagnostics Limited in its latest financial disclosures. While the company has managed to avoid bad debt write-offs, this working capital strain remains a material risk.

Another concern is the pricing framework. Government contracts typically fix diagnostic pricing at rates lower than retail markets, which compresses margins. To maintain profitability, diagnostics companies must ensure tight cost control, efficient staffing, and high test throughput, which requires disciplined execution and scale advantages.

There are also operational complexities associated with integrating services within public hospitals. Staff training, data sharing, equipment maintenance, and adherence to quality standards must be tightly managed across distributed sites. Moreover, political risk exists. Contracts may be delayed, revised, or even canceled depending on changes in state leadership or policy shifts.

Some states have also faced criticism for outsourcing diagnostic services. Civil society groups have raised concerns around service quality, pricing, and accountability, particularly when PPPs are implemented without clear performance monitoring. These risks require diagnostics companies to maintain transparency, invest in training, and uphold internationally accepted standards to preserve both reputation and contract viability.

How might the PPP model drive the next wave of diagnostics growth in India?

Going forward, the PPP model is expected to play a pivotal role in scaling diagnostics access in India. With healthcare infrastructure expanding under both central and state programs, the need for reliable diagnostic partners is growing rapidly. Companies that can deliver high-quality services at scale, backed by technology and accreditation, are well-positioned to benefit from this structural tailwind.

Industry reports estimate that the Indian diagnostics market could grow at a compound annual growth rate of 14 to 17 percent, with a significant portion of this growth coming from public sector partnerships. As more states adopt PPP frameworks and standardize tender terms, the opportunity for private players to build institutional revenue streams will expand. Diagnostics providers that align with national health priorities, invest in digital platforms, and maintain operational excellence could capture long-term value by embedding themselves into the core of India’s healthcare delivery network.

Technology will also accelerate this shift. Cloud-based reporting, AI-assisted screening tools, and remote diagnostic workflows are enabling diagnostics companies to serve geographies that were previously unreachable. These innovations are particularly compatible with the PPP model, where speed, efficiency, and standardization are crucial.

What should investors and stakeholders be watching in diagnostics PPPs?

For institutional investors, PPP-based diagnostics businesses offer an alternative to traditional retail models. Investors should focus on contract win rates, duration and pricing terms, revenue visibility, and working capital metrics. Monitoring government policy shifts, tender activity, and health budget allocations at the state level can provide early signals on market expansion or risk factors.

Accreditations, service quality, and technology deployment will continue to act as key differentiators. Companies like Krsnaa Diagnostics Limited that combine strong PPP credentials with internationally recognized clinical quality are likely to be more competitive in future bids and tenders.

Ultimately, public-private partnerships may not just be a supplement to diagnostics growth in India but the engine driving equitable, sustainable, and scalable healthcare delivery for the next decade.